Skin Sympathetic Nerve Activity Precedes the Onset and Termination of Paroxysmal Atrial Tachycardia and Fibrillation

First Author's surname: Uradu and Wan

Short Title: SKNA and atrial tachyarrhythmia

Andrea Uradu, MD,1 Juyi Wan, MD,1,4 Anisilia Doytchinova, MD,1 Keith C. Wright, MS,1 Andrew Y. T. Lin, BS,1 Lan S. Chen, MD,2 Changyu Shen, PhD,3 Shien-Fong Lin, PhD, FHRS,5 Thomas Everett, IV, PhD, FHRS1 and Peng-Sheng Chen, MD, FHRS1

*These two authors contributed equally to this manuscript

Institution: 1 the Krannert Institute of Cardiology, Division of Cardiology, Department of Medicine, and 2 Division of Pediatric Neurology, Department of Neurology, Indiana University School of Medicine, Indianapolis, IN; 3 the Richard and Susan Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 4 Department of Cardiothoracic Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China and 5 Institute of Biomedical Engineering, National Chiao-Tung University, Hsin-Chu, Taiwan

Address for Correspondence:
Peng-Sheng Chen, MD, 1800 N. Capitol Ave, E475, Indianapolis, IN 46202
Phone: 317-274-0909, Fax: 317-962-0588, Email: chenpp@iu.edu

Total word count: 4976

Disclosures: Shien-Fong Lin and Peng-Sheng Chen have equity interests in Arrhythmotech, LLC.

This is the author's manuscript of the article published in final edited form as:

Abstract

Background: Skin sympathetic nerve activity (SKNA) is useful in estimating sympathetic tone in humans.

Objective: To test the hypothesis that (1) increased SKNA is associated with the onset and termination of paroxysmal atrial tachycardia (AT) and AF and (2) The sinoatrial node (SAN) response to SKNA is reduced in patients with more frequent of AT or AF.

Methods: SKNA and electrocardiogram were recorded in 11 patients (4 males and 7 females, average age 66±10 years), including 3 patients with AT (11±18 episodes/patient) and 8 patients with AF (24±26 episodes/patient).

Results: The average SKNA (aSKNA, in µV) 10 s prior to AT onset were 1.07±0.10; 10 s after termination were 1.27±0.10, both were significantly (p=0.032, p<0.0001) higher than that during sinus rhythm (0.97±0.09). The aSKNA 10 s prior to AF onset were 1.34±0.07 and 10 s after termination were 1.31±0.07. Both were significantly (p<0.0001) higher than that during sinus rhythm (1.04±0.07). The aSKNA before onset (p<0.0001) and after termination (p= 0.0011) were both higher in AF than in AT. The sinus rate correlated (p<0.0001) with aSKNA in each patient (average r: 0.74, 95% confidence interval (CI): 0.65-0.84). The r in each patient negatively correlated with the number of AT and AF episodes (r= - 0.6493, 95% confidence interval:-0.8990 to -0.08073, p=0.0306).

Conclusions: Increased SKNA was observed both at onset and termination of AT and AF. The patients with more frequent AT and AF episodes had less of a correlation between sinus rate and aSKNA, suggesting SAN remodeling by tachycardia.

Key words: arrhythmia; autonomic nervous system; cardiac electrophysiology; sick sinus syndrome;
Introduction

It is well documented that the autonomic nervous system plays an important role in arrhythmogenesis in both animal models and in humans. Studies in ambulatory dogs documented an association between stellate ganglion nerve activity (SGNA) and the paroxysmal atrial tachyarrhythmias, including both atrial tachycardia (AT) and atrial fibrillation (AF). However, the invasive nature of SGNA monitoring limits its use in humans. The skin of the thorax and upper extremities is well innervated by sympathetic nerves. Tracer studies showed that the somata of these nerves originate in the cervical and stellate ganglia. It is therefore possible that the sympathetic nerve activity recorded from the skin might be used to estimate SGNA. Consistent with the latter hypothesis, we found that subcutaneous nerve activity (SCNA) and surface skin sympathetic nerve activity (SKNA) in ambulatory dogs correlated well with SGNA. In addition, SCNA is more effective than heart rate variability in estimating the sympathetic tone. Encouraged by these results, we showed that it is possible to simultaneously record electrocardiogram (ECG) and SKNA using conventional ECG electrodes in humans. The same electrical signal can be filtered between 0.5 Hz and 150 Hz to display ECG, while high pass filtered at 200 Hz or higher to display SKNA. We named this recording method the neuECG because it is a method to simultaneously record neural discharges and ECG. The validity of neuECG recording was supported by the characteristics of nerve discharges recorded during cold water pressor test, Valsalva maneuvers and also by the correlation with heart rate and ventricular arrhythmias. In addition, lidocaine injection into the stellate ganglion abruptly reduced SKNA. The availability of neuECG made it feasible to test the hypothesis that sympathetic nerve activity is a direct trigger of paroxysmal AT and AF episodes in humans. Additionally, sick sinus syndrome is a commonly associated with atria tachyarrhythmias. Because reverse remodeling of sinoatrial node (SAN) function may occur after catheter ablation of AF, AT and AF may play an important role in the pathogenesis of sinus node dysfunction. Abnormal response of superior SAN to sympathetic stimulation is a
characteristic finding in patients with AF and symptomatic bradycardia. Because SKNA can be
used to estimate sympathetic tone in humans, increased SKNA should result in a higher heart
rate (HR). We hypothesize that the correlation between the average SKNA (aSKNA) and HR
would be less in patients with higher frequency of AT and AF compared to those with lower
frequency of AT and AF. The purpose of the present study was to test the hypotheses that
increased SKNA is associated with the onset of AT and AF in humans, and that the frequency of
AT and AF episodes is negatively associated with SAN response to sympathetic tone.

Methods
This research protocol was approved by the Institutional Review Board of the Indiana University
School of Medicine. We reviewed the live telemetry recording of the inpatients and prospectively
identified 11 patients (6 male, age 46 to 79) with paroxysmal atrial tachyarrhythmia for neuECG
recording. Written and informed consent was obtained from each patient.

Continuous neuECG Monitoring
We used a modified portable ME6000 Biomonitor (Mega Electronics Ltd, Finland) for data
acquisition. One channel was used to record ECG lead I on the chest with negative and
positive electrodes in the right and left subclavian areas, respectively. A second channel was
used to record SKNA from the right arm. The signals from neuECG were amplified and
bandpass filtered (0.5 Hz-150 Hz) to show ECG. The same signals were bandpass filtered from
500 Hz-1000 Hz to show SKNA. We analyzed recordings from all channels using custom-written
software.

Average SKNA and heart rate before onset and after termination of AT and AF
AF was defined by a sudden onset of rapid irregular atrial activations with irregular ventricular
responses. AT was defined by a sudden change from sinus rhythm to rapid (> 100 bpm) and
regular narrow QRS tachycardia. All onset and termination of the arrhythmia episodes were spontaneous. To determine the aSKNA and HR before and after termination of AT and AF, all AT and AF episodes lasting at least 10 s and separated by ≥ 10 s were identified. Shorter episodes were not included in the analyses. We integrated all digitized SKNA signals over that time window and divided the total voltage by the number of digitized samples in the same window to obtain the average voltage of aSKNA per sample. So that we can compare SKNA with traditional microneurography tracings, we also integrated SKNA over every 100 ms and plotted the results over time in the figures. The aSKNA and HR 10 s before onset, during the last 10 s of arrhythmia and within 10 s after termination of these AT and AF were analyzed. The frequency of AT or AF episodes were defined by the ratio between total episodes and the duration (hours) monitored.

Statistical analysis
Continuous variables were summarized by mean and standard deviation; categorical variables were summarized by frequency and percentage. Repeated measure ANOVA models were fitted first to perform an overall test to determine if continuous outcomes under different conditions have the same mean values. If the test was significant, paired T test was used to perform post-hoc pairwise comparisons. Pearson correlation coefficient was used to measure linear correlation between continuous variables and Bonferroni correction was used to adjust significance level due to multiple tests. Linear mixed-effects models were used to analyze AT and AF episodes where subjects were treated as the random effect. All 95% confidence intervals are based on normal distributions of the measurements. Two-sided p values ≤0.05 were considered statistically significant.

Results
Patient characteristic
The patient characteristics are shown in Table 1. We have a total of 11 patients, including 4 males and 7 females with an average age of 66±10 years. Among them, 3 patients had AT and 8 patients had AF. None of them had both types of arrhythmias. There were no complications associated with recording.

**Average SKNA increases prior to onset and after termination of AT**

We manually reviewed 34 episodes of AT in 3 patients (11±18 per patient). Among them, patient #10 had 32 episodes of AT while patients 1 and 4 had one episode each. The AT duration averaged 23.7±18.7 s. Figure 1 shows 2 episodes of AT from patient #10. Similar to that found in ambulatory dogs, the onset of AT was preceded by increased SKNA (black arrows). In addition, there was a burst of SKNA and transient HR acceleration (by > 10 bpm in 31 and by > 5 bpm in one episode) prior to AT termination (blue arrows). The same phenomenon was not found in the remaining 2 patients (Figure 2). Statistically, the aSKNA (µV) 10 s prior to AT onset was 1.07±0.10, during the final 10 s of AT was 1.20±0.10, 10 s after termination was 1.27±0.10; all were significantly (p=0.032, p<0.0001, p<0.0001, respectively) higher than that during sinus rhythm (0.97±0.09) of the same patients.

**Average SKNA increases prior to onset and after termination of AF**

There was a total of 188 episodes of AF in 8 patients (24±26 per patient). The AF duration averaged 471.0±886.5 s. SKNA is significantly increased at the onset (Figure 3), during the final 10 s and within 10 s after termination of AF (Figure 4). In one episode, two beats of premature atrial contractions (PAC) preceded AF onset (3B, blue arrows). Statistically, the aSKNA (µV) 10 s prior to the onset was 1.34±0.07, during the final 10 s of AF was 1.29±0.07, 10 s after termination was 1.31±0.07; all were significantly (p<0.0001) higher than that of sinus rhythm (1.04±0.07).
AF is associated with higher average SKNA than AT

We compared the aSKNA and HR during sinus rhythm and all AT and AF episodes 10 s before onset, during final 10 s of the episode, and 10 s after termination (Figure 5). The aSKNA associated with arrhythmias were mostly higher than that during sinus rhythm, but there were apparent overlaps of aSKNA associated with sinus rhythm and that with AT or AF. There was no threshold aSKNA above which AT or AF reliably followed. The aSKNA before onset, during the final 10 s and after termination in AF were both significantly higher than that associated with AT episodes (p<0.0001, < 0.0001 and p= 0.0011, respectively), although large overlaps of aSKNA also existed between these two groups.

Average SKNA and HR vs frequency of atrial tachyarrhythmia

aSKNA and HR positively correlated with each other in all 11 patients (p<0.0001, average r: 0.74, 95% CI: 0.65-0.84) (Figure 6A). Interestingly, the correlation coefficient of each patient negatively correlated with the number of AT and AF episodes per hour (r= - 0.6493, 95% confidence interval:-0.8990 to -0.08073, p=0.0306; Figure 6B). In other words, the higher the number of AT or AF episodes, the less responsive the SAN is to sympathetic activation. One outlier (black arrow in 6B) had > 100 short runs of AT but we only included 32 episodes (those lasted 10 s or longer) in this analyses.

Discussion

In this study we demonstrate several findings: (1) Distinct bursts in SKNA are associated with both onset and termination of paroxysmal atrial tachyarrhythmia. (2) aSKNA is increased before onset, during final 10 s and after termination of AF and AT compared to sinus rhythm. (3) aSKNA associated with AF are higher than that associated with AT. (4) aSKNA positively correlates with HR. However, the correlation becomes less strong as the frequency of AF and
AT increases, suggesting the frequency of AF and AT is a major factor responsible for SAN dysfunction.

**Autonomic mechanisms of AF onset**

The heart is heavily innervated by the autonomic nerves. This includes extrinsic and an intrinsic cardiac nervous system, both of which consists of sympathetic and parasympathetic components and are important in arrhythmogenesis. In ambulatory dogs, both extrinsic and intrinsic cardiac nerve activations frequently precede the onset of spontaneous AT and AF. Ablation of the stellate ganglion or the ganglionated plexi (GP) reduced or eliminated these atrial arrhythmias. In humans, unilateral temporary stellate ganglion block might reduce AF inducibility and decrease AF duration. The neural mechanisms of AF is further substantiated by randomized controlled clinical trials that showed pulmonary vein isolation (PVI) plus GP ablation offered a 20-25% higher success rate compared to PVI alone in patients with AF. Another randomized trial showed that botulinum toxin injection in epicardial fat pads can prevent recurrences of AF after cardiac surgery. While epicardial fat pad ablation does not have long-term effects in animal models, the same group of authors have later concluded that extensively ablating LA covering GP areas along with pulmonary vein antrum isolation enhanced the denervation of autonomic nerve system and seemed to improve procedural outcome in patients with AF.

On the other hand a recent study by Driessen et al concluded that GP ablation in addition to PVI and LA lines in patients with advanced AF (defined as persistent AF, enlarged left atria, or previously failed catheter ablation) did not reduce AF recurrence and had increased episodes of AT 12 months after surgery. We propose that there are several possibilities for this discrepancy. First, while important in inducing AF, GP activity may not be important in AF maintenance. Cryoablation of the stellate ganglia and cardiac branches of vagal nerve only prevented paroxysmal AF but not persistent AF in canine models. Therefore, the fact that
Driessen et al recruited patients with advanced (persistent) AF, many with prior failed ablations, may have significant implications on the results of the study. In contrast, Katritsis et al only recruited patients with paroxysmal AF and no prior ablation to the study, thus demonstrated the benefit of GP ablation. Secondly, Driessen et al may have concluded the study too early. In a study that compared PVI and GP ablation vs PVI and linear ablation in persistent AF, statistically significant difference was noted at 3-year follow up, but not at 1-year. The results of Driessen et al also shown a trend towards better outcomes for both paroxysmal and persistent AF at 1 year, but the differences were not statistically significant. It is possible that longer follow up is needed to demonstrate significant differences.

The results of the present study provided further support of the neural mechanisms of AT and AF by directly measuring the sympathetic nerve activity in patients with spontaneous episodes of these arrhythmias. However, in some patients the aSKNA prior to onset of AT/AF overlapped significantly with the range of aSKNA during sinus rhythm. In those patients, the benefit of neuromodulation might be marginal. Further studies are needed to test the hypothesis that SKNA recording might be helpful in selecting patients for neuromodulation procedures.

**Bursts of SKNA prior to atrial tachycardia termination**

We demonstrated in one patient that all 32 AT episodes were terminated by a burst of SKNA and a brief acceleration of the heart rate. That sequence of events suggest that transient SKNA burst may be important in terminating AT, probably by overdrive suppression of the arrhythmia. In that patient, suppression of sympathetic tone by either drugs or non-pharmaceutical methods may have both antiarrhythmic and proarrhythmic effects. However, that phenomenon was not observed in the other 2 AT patients. The relationship between sympathetic tone and AT onset/termination may vary from patient to patient. Neuromodulation therapy may be beneficial in some patients, but is unlikely to be uniformly successfully in controlling AT and AF. Whether
or not neuECG is helpful in selecting patients for neuromodulation therapy deserves further

study.

Sinoatrial node dysfunction secondary to atrial tachyarrhythmia
We found that the aSKNA and HR correlated with each other. However, the correlation
coefficients reduced as the frequencies of AT and AF increased. This finding suggests that SAN
was remodeled and became less responsive to sympathetic stimulation in patients with more
frequent AT and AF episodes. The association between SAN dysfunction and certain cardiac
conditions, such as AF or heart failure, has been well described. In a study by Elvan et al.,
pacing-induced chronic AF (2-6 weeks) induced SAN dysfunction, as evidenced by prolongation
of SAN recovery time and decreases in intrinsic heart rates. Similar conclusions have been
reported in humans. Moreover, it appears that the SAN dysfunction can be reversed after AF
ablation. Acceleration of the calcium clock in the superior SAN plays an important role in sinus
rate acceleration during beta-adrenergic stimulation. Abnormal responses of superior SAN to
sympathetic stimulation is a characteristic finding in patients with AF and symptomatic
bradycardia. Our results suggest that frequent tachyarrhythmia episodes may have remodeled
the superior SAN and reduced the calcium clock response during sympathetic stimulation.
Another implication is that the relationship between aSKNA and HR may be an indication of the
AT and AF burden; a low r value suggests a high AF or AT burden.

Limitations of the study
Because the skin does not have parasympathetic nerves, SKNA can be used to specifically
measure sympathetic but not parasympathetic tone. Our data could not be used to test the
hypothesis that simultaneous sympathovagal discharges are often needed to induce AT and
AF. An important new observation was that a burst of SKNA can accelerate AT rate, leading to
AT termination. However, we only have one patient with that observation. It is not possible to
generalize these results to other AT patients. We do not have data in this study to determine if
SKNA is causally related to AT/AF onset or termination. Due to the limitation of the equipment,
we were limited to study hospitalized patients. These patients may not be representative of all
patients with AT/AF. The study was not done during drug-free state, and the drugs can affect
the results of the study. The same size is small, thus prevented effective subgroup analyses.

Conclusions
We conclude that increased SKNA is associated with both the onset and termination of AT and
AF. The patients with more AT and AF episodes had less of a correlation between sinus rate
and aSKNA, suggesting SAN remodeling by tachycardia episodes. These findings also suggest
that SKAN may be a useful non-invasive tool in studying the neural mechanisms of cardiac
arrhythmia.

Acknowledgements
Supported by a fellowship award from the American Heart Association (Dr Doytchinova), NIH
grants R41 HL124741, R42 DA043391 (Dr Everett), P01 HL78931, R01 HL71140 (Dr Chen), a
Charles Fisch Cardiovascular Research Award endowed by Dr Suzanne B. Knoebel of the
Krannert Institute of Cardiology (Dr Everett), a Medtronic-Zipes Endowment and the Indiana
University Health-Indiana University School of Medicine Strategic Research Initiative (Dr Chen).
We thank Roxanne Kovacs, RN, MSN for her assistance.
References


1 **Table 1.** Patient characteristics

<table>
<thead>
<tr>
<th>#</th>
<th>Age</th>
<th>Gender</th>
<th>Diagnoses</th>
<th>CHA2DS2-VASc score</th>
<th>Antiarrhythmic medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>63</td>
<td>Female</td>
<td>Hyperlipidemia, Hypertension</td>
<td>2</td>
<td>Metoprolol</td>
</tr>
<tr>
<td>2</td>
<td>46</td>
<td>Female</td>
<td>End-stage kidney disease, Diabetes, Hypertension, Hyperlipidemia</td>
<td>3</td>
<td>Metoprolol</td>
</tr>
<tr>
<td>3</td>
<td>65</td>
<td>Female</td>
<td>Lung transplant, Diastolic heart failure</td>
<td>3</td>
<td>Amiodarone, Metoprolol</td>
</tr>
<tr>
<td>4</td>
<td>59</td>
<td>Male</td>
<td>Hypertension, Hyperlipidemia, Lung transplant</td>
<td>1</td>
<td>Amiodarone, Metoprolol</td>
</tr>
<tr>
<td>5</td>
<td>74</td>
<td>Female</td>
<td>Diastolic heart failure, Metastatic renal cell carcinoma</td>
<td>3</td>
<td>Metoprolol</td>
</tr>
<tr>
<td>6</td>
<td>79</td>
<td>Female</td>
<td>Coronary artery disease, Coronary artery bypass grafting, Hyperlipidemia, Hypertension</td>
<td>4</td>
<td>Amiodarone, Metoprolol</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>Male</td>
<td>Aortic dilation, Aortic valve replacement</td>
<td>1</td>
<td>Amiodarone</td>
</tr>
<tr>
<td>8</td>
<td>74</td>
<td>Male</td>
<td>Coronary artery disease, Severe aortic stenosis</td>
<td>3</td>
<td>Metoprolol</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 9 | 68 | Male | Coronary artery disease  
Myocardial infarction  
Abdominal aortic aneurysm  
Hypertension  
Hyperlipidemia  
Factor V Leiden deficiency. |
|  |  |  | Amiodarone  
Metoprolol  
Verapamil |
| 10 | 66 | Female | Hypertension  
Diabetes  
End stage kidney disease |
|  |  |  | Metoprolol |
| 11 | 78 | Female | Coronary Artery Disease  
Coronary Artery Bypass  
Heart Failure  
Mitral valve replacement  
Tricuspid valve replacement  
Chronic Kidney Disease  
Chronic Anemia |
|  |  |  | Carvedilol |
Figure 1. SKNA characteristics before onset and after termination of AT in patient #10, who has 32 episodes of AT fulfilling the inclusion criteria. Signals were high bandpass filtered from 500 Hz-1000 Hz to reveal SKNA and from 0.5 Hz-150 Hz to reveal ECG. iSKNA was obtained by integrating the voltage of digitized data over 100 ms windows. (A) Multiple episodes of SKNA bursts (black arrows) were present within 30 s (double headed arrows) prior to AT onset. Heart rate acceleration (green arrows) associated with SKNA burst (blue arrows) was observed prior to AT termination (red dotted line). This phenomenon was present in all 32 AT termination episodes analyzed for this patient. SKNA continues to be elevated during the 30 s after termination. SKNA was also increased during premature atrial contraction (arrowhead). (B) Similar findings in a separate AT episode, consistent with (A).
Figure 2. NeuECG recording of an AT episode from patient #1. SKNA is slightly elevated prior to (blue arrows) and at the onset of AT (downward black arrows). A short burst of SKNA (blue arrows) was observed prior to termination, but was not associated with HR acceleration. There was no SKNA elevation after termination. Each double headed arrow indicates 30 s.
Figure 3. NeuECG recording of AF onset in patient #7. (A) SKNA is significantly increased prior to AF onset (black arrows). Double arrows indicate 10 s. (B) Similar findings in a separate AF episode of the same patient. SKNA is significantly increased prior to AF onset (black arrows). Two beats of premature atrial contractions preceded the onset (blue arrows), also associated with higher SKNA.
Figure 4. NeuECG recording of AF termination. (A) Significant increase in SKNA was observed in patient #7 before and after spontaneous termination of AF (black arrows). The double arrows indicate 10 s. A premature atrial contraction was recorded after termination of AF (blue arrow). (B) Similar to (A), increased SKNA was observed before and after termination of AF in patient #8.
Figure 5. Characteristics of aSKNA and HR before, during last 10 s, and after AF or AT episodes. aSKNA before onset (red), during final 10 s (green) and after termination (blue) of both AT and PF episodes is greater than that of sinus rhythm (black) (p<0.0001). Overall, aSKNA before onset, during final 10 s and after termination of AF were both higher than that of AT. However, there is significant overlap within and variation among different individuals. For example, patient #10 had AT, but the aSKNA in this particular patient is higher than the other AT patients (#1, #4), as well as several AF patients (#3, #8, #11).
Figure 6. Correlation between aSKNA and HR and its relationship to frequency of AT or AF. (A) aSKNA and HR positively correlated with each other in all 11 patients. (B) Correlation coefficient of each patient is inversely correlated to the frequency of AT or AF episodes in the same patient. The more frequent a patient has AT or AF episodes, the less sensitive their HR is to sympathetic activation as detected by neuECG via skin. The outlier (black arrow) is from patient #10, who had > 100 short runs of AT but only 32 was ≥ 10 s and were included in the analyses. If we included all short burst of AT in the analyses, then his r value may not be lower than expected.